Skip to main content


AWMSG Strategy for Wales: 2024-2029
Read our latest newsletter
Blueteq High Cost Drug System

The Blueteq High Cost Drugs (HCD) system will allow health boards to monitor the prescribing of high-cost medicines and manage the ever-increasing complexities associated with their use. Documents and a list of FAQs are available from this page.

Maximising the opportunity presented by biosimilar medicines – A national strategy for Wales
Lay members

Our committees need lay members to represent the general public and be the voice of patients and carers in Wales. This page tells you more about the role of a lay member, what's involved and how you can get in touch with us to find out more.

AWMSG static list

Recommendations are moved to the static list when, after AWTTC review, it is clear that no new evidence is likely to be published that would have any material effect on the current advice. Recommendations placed on the static list may be transferred back to the list for further appraisal if new evidence becomes available that is likely to have a material effect on the recommendation issued.

New AWTTC website feedback
Get involved in our work

If you're a patient, carer, patient organisation, or an interested member of the public, we'd like to hear your views and experiences. 

Follow AWTTC: